Literature DB >> 16965535

FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2.

Inken Wierstra1, Jürgen Alves.   

Abstract

FOXM1c transactivates the c-myc promoter via the P1 and P2 TATA boxes using a new mechanism. Whereas the P1 TATA box TATAATGC requires its sequence context to be FOXM1c responsive, the P2 TATA box TATAAAAG alone is sufficient to confer FOXM1c responsiveness to any minimal promoter. FOXM1c transactivates by binding to the TATA box as well as directly to TATA-binding protein, transcription factor IIB and transcription factor IIA. This new transactivation mechanism is clearly distinguished from the function of FOXM1c as a conventional transcription factor. The central domain of FOXM1c functions as an essential domain for activation via the TATA box, but as an inhibitory domain (retinoblastoma protein-independent transrepression domain and retinoblastoma protein-recruiting negative regulatory domain) for transactivation via conventional FOXM1c-binding sites. Each promoter with the P2 TATA box TATAAAAG is postulated to be transactivated by FOXM1c. This was demonstrated for the promoters of c-fos, hsp70 and histone H2B/a. A database search revealed almost 300 probable FOXM1c target genes, many of which function in proliferation and tumorigenesis. Accordingly, dominant-negative FOXM1c proteins reduced cell growth approximately threefold, demonstrating a proliferation-stimulating function for wild-type FOXM1c.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965535     DOI: 10.1111/j.1742-4658.2006.05468.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  23 in total

1.  FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression.

Authors:  Samuel K M Li; David K Smith; Wai Ying Leung; Alice M S Cheung; Eric W F Lam; Goberdhan P Dimri; Kwok-Ming Yao
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

2.  FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Authors:  Chen Huang; Dacheng Xie; Jiujie Cui; Qi Li; Yong Gao; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-01-22       Impact factor: 12.531

Review 3.  Forkhead box M1 transcription factor: a novel target for cancer therapy.

Authors:  Zhiwei Wang; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Cancer Treat Rev       Date:  2009-12-22       Impact factor: 12.111

Review 4.  Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.

Authors:  Li Gu; Han-Min Liu
Journal:  World J Pediatr       Date:  2019-06-12       Impact factor: 2.764

5.  Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function.

Authors:  Jinglei Zhang; Chengfu Yuan; Jianguo Wu; Zeinab Elsayed; Zheng Fu
Journal:  J Biol Chem       Date:  2014-12-22       Impact factor: 5.157

Review 6.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

7.  Antiviral response dictated by choreographed cascade of transcription factors.

Authors:  Elena Zaslavsky; Uri Hershberg; Jeremy Seto; Alissa M Pham; Susanna Marquez; Jamie L Duke; James G Wetmur; Benjamin R Tenoever; Stuart C Sealfon; Steven H Kleinstein
Journal:  J Immunol       Date:  2010-02-17       Impact factor: 5.422

Review 8.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

9.  DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Authors:  Jinfei Xu; Joseph R Testa
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

10.  Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Xiangdong Le; Chen Huang; Zhiliang Jia; Jiujie Cui; Suyun Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.